These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 26863632)

  • 61. Promotion of hepatocellular carcinoma metastasis through matrix metalloproteinase activation by epithelial-mesenchymal transition regulator Twist1.
    Zhao XL; Sun T; Che N; Sun D; Zhao N; Dong XY; Gu Q; Yao Z; Sun BC
    J Cell Mol Med; 2011 Mar; 15(3):691-700. PubMed ID: 20219012
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Actin-like 6A predicts poor prognosis of hepatocellular carcinoma and promotes metastasis and epithelial-mesenchymal transition.
    Xiao S; Chang RM; Yang MY; Lei X; Liu X; Gao WB; Xiao JL; Yang LY
    Hepatology; 2016 Apr; 63(4):1256-71. PubMed ID: 26698646
    [TBL] [Abstract][Full Text] [Related]  

  • 63. MicroRNA-200a inhibits epithelial-mesenchymal transition in human hepatocellular carcinoma cell line.
    Zhong C; Li MY; Chen ZY; Cheng HK; Hu ML; Ruan YL; Guo RP
    Int J Clin Exp Pathol; 2015; 8(9):9922-31. PubMed ID: 26617701
    [TBL] [Abstract][Full Text] [Related]  

  • 64. MiR-25 promotes hepatocellular carcinoma cell growth, migration and invasion by inhibiting RhoGDI1.
    Wang C; Wang X; Su Z; Fei H; Liu X; Pan Q
    Oncotarget; 2015 Nov; 6(34):36231-44. PubMed ID: 26460549
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Incomplete radiofrequency ablation enhances invasiveness and metastasis of residual cancer of hepatocellular carcinoma cell HCCLM3 via activating β-catenin signaling.
    Zhang N; Wang L; Chai ZT; Zhu ZM; Zhu XD; Ma DN; Zhang QB; Zhao YM; Wang M; Ao JY; Ren ZG; Gao DM; Sun HC; Tang ZY
    PLoS One; 2014; 9(12):e115949. PubMed ID: 25542041
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Overexpression of miR-200a suppresses epithelial-mesenchymal transition of liver cancer stem cells.
    Wang J; Yang X; Ruan B; Dai B; Gao Y; Duan J; Qu S; Tao K; Dou K; Li H
    Tumour Biol; 2015 Apr; 36(4):2447-56. PubMed ID: 25412960
    [TBL] [Abstract][Full Text] [Related]  

  • 67. CBX8 exhibits oncogenic properties and serves as a prognostic factor in hepatocellular carcinoma.
    Tang B; Tian Y; Liao Y; Li Z; Yu S; Su H; Zhong F; Yuan G; Wang Y; Yu H; Tomlinson S; Qiu X; He S
    Cell Death Dis; 2019 Jan; 10(2):52. PubMed ID: 30718464
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Methylenetetrahydrofolate dehydrogenase 2 overexpression is associated with tumor aggressiveness and poor prognosis in hepatocellular carcinoma.
    Liu X; Huang Y; Jiang C; Ou H; Guo B; Liao H; Li X; Yang D
    Dig Liver Dis; 2016 Aug; 48(8):953-60. PubMed ID: 27257051
    [TBL] [Abstract][Full Text] [Related]  

  • 69. STAT3 cooperates with Twist to mediate epithelial-mesenchymal transition in human hepatocellular carcinoma cells.
    Zhang C; Guo F; Xu G; Ma J; Shao F
    Oncol Rep; 2015 Apr; 33(4):1872-82. PubMed ID: 25653024
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Knockdown of FRAT1 inhibits hypoxia-induced epithelial-to-mesenchymal transition via suppression of the Wnt/β-catenin pathway in hepatocellular carcinoma cells.
    Fan WH; Du FJ; Liu XJ; Chen N
    Oncol Rep; 2016 Nov; 36(5):2999-3004. PubMed ID: 27666874
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Critical role of DEK and its regulation in tumorigenesis and metastasis of hepatocellular carcinoma.
    Yu L; Huang X; Zhang W; Zhao H; Wu G; Lv F; Shi L; Teng Y
    Oncotarget; 2016 May; 7(18):26844-55. PubMed ID: 27057626
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Epigenetic reader BRD4 inhibition as a therapeutic strategy to suppress E2F2-cell cycle regulation circuit in liver cancer.
    Hong SH; Eun JW; Choi SK; Shen Q; Choi WS; Han JW; Nam SW; You JS
    Oncotarget; 2016 May; 7(22):32628-40. PubMed ID: 27081696
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Down-regulation of Transducin-Like Enhancer of Split protein 4 in hepatocellular carcinoma promotes cell proliferation and epithelial-Mesenchymal-Transition.
    Wu XC; Xiao CC; Li H; Tai Y; Zhang Q; Yang Y
    Biochem Biophys Res Commun; 2016 Aug; 477(2):161-6. PubMed ID: 27297112
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The Histone Variant H2A.Z Is a Master Regulator of the Epithelial-Mesenchymal Transition.
    Domaschenz R; Kurscheid S; Nekrasov M; Han S; Tremethick DJ
    Cell Rep; 2017 Oct; 21(4):943-952. PubMed ID: 29069602
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Expression and inhibitory role of TIMP-3 in hepatocellular carcinoma.
    Shen B; Jiang Y; Chen YR; Zheng HC; Zeng W; Li YY; Yin A; Nie Y
    Oncol Rep; 2016 Jul; 36(1):494-502. PubMed ID: 27222429
    [TBL] [Abstract][Full Text] [Related]  

  • 76. RNF2 inhibits E-Cadherin transcription to promote hepatocellular carcinoma metastasis via inducing histone mono-ubiquitination.
    Yao L; Li J; Jiang B; Zhang Z; Li X; Ouyang X; Xiao Y; Liu G; Wang Z; Zhang G
    Cell Death Dis; 2023 Apr; 14(4):261. PubMed ID: 37037816
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Role of H2A.Z.1 in epithelial-mesenchymal transition and radiation resistance of lung adenocarcinoma in vitro.
    Zheng Y; Han X; Wang T
    Biochem Biophys Res Commun; 2022 Jun; 611():118-125. PubMed ID: 35525100
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Histone Variant H2A.Z.2 Mediates Proliferation and Drug Sensitivity of Malignant Melanoma.
    Vardabasso C; Gaspar-Maia A; Hasson D; Pünzeler S; Valle-Garcia D; Straub T; Keilhauer EC; Strub T; Dong J; Panda T; Chung CY; Yao JL; Singh R; Segura MF; Fontanals-Cirera B; Verma A; Mann M; Hernando E; Hake SB; Bernstein E
    Mol Cell; 2015 Jul; 59(1):75-88. PubMed ID: 26051178
    [TBL] [Abstract][Full Text] [Related]  

  • 79. H2A.Z overexpression suppresses senescence and chemosensitivity in pancreatic ductal adenocarcinoma.
    Ávila-López PA; Guerrero G; Nuñez-Martínez HN; Peralta-Alvarez CA; Hernández-Montes G; Álvarez-Hilario LG; Herrera-Goepfert R; Albores-Saavedra J; Villegas-Sepúlveda N; Cedillo-Barrón L; Montes-Gómez AE; Vargas M; Schnoor M; Recillas-Targa F; Hernández-Rivas R
    Oncogene; 2021 Mar; 40(11):2065-2080. PubMed ID: 33627784
    [TBL] [Abstract][Full Text] [Related]  

  • 80. H2AFZ Is a Prognostic Biomarker Correlated to TP53 Mutation and Immune Infiltration in Hepatocellular Carcinoma.
    Dong M; Chen J; Deng Y; Zhang D; Dong L; Sun D
    Front Oncol; 2021; 11():701736. PubMed ID: 34760688
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.